How effective is Lusutrombopag?

Lusutrombopag is a drug used to treat thrombocytopenia caused by chronic liver disease, especially in patients who require invasive surgery. Thrombocytopenia is a blood disorder caused by a reduced number of platelets, an important component of blood that helps blood clot and prevent bleeding. In patients with chronic liver disease, platelet counts may decrease significantly, which increases the risk of bleeding complications during invasive procedures such as incisions in the skin or insertion of instruments.

The therapeutic effect of Rutrombopag has been fully verified in multiple clinical studies. Two major clinical trials evaluated the effectiveness of rutrombopag in improving platelet counts and reducing the need for transfusions in patients with thrombocytopenia due to chronic liver disease. In the first study, a total of 96 adults participated. The study results showed that 79% of patients taking Rutrombopag did not require platelet transfusions before surgery, while only 13% of patients taking placebo were able to avoid blood transfusions. This showed that Rutrombopag significantly increased patients' platelet counts, thereby reducing the need for platelet transfusions during surgery.

In the second study, the number of participants increased to 215 adults. The study results also showed that 65% of patients taking Rutrombopag did not require platelet transfusions before surgery, while only 29% of patients taking placebo did not require blood transfusions. This study further validates the effectiveness of Rutrombopag in increasing platelet counts and reducing the need for transfusions.

The therapeutic effect of Rutrombopag is not only reflected in increasing platelet counts, but also plays an important role in reducing the risk of bleeding during surgery and reducing the need for blood transfusions. By effectively increasing platelet levels, Rutrombopag provides better treatment options for liver disease patients who require invasive surgery, reducing bleeding complications due to thrombocytopenia, thereby improving patients' surgical safety and postoperative recovery quality.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo